Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product
Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product
Cogent manufactures, packages and labels the CBG lozenge, a novel dissolvable format and is easy to dose.Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, announced on Monday the launch of the newly developed Luo CBD lozenge.
加拿大醫療大麻公司極光大麻（納斯達克：ACB）（tsx：ACB）與創新健康保健公司Vectura Fertin Pharma，Inc.在週一宣佈推出新開發的Luo CBD潤喉片。
What Happened
發生了什麼
The product was developed by Vectura Fertin Pharma, and represents the company's first medical cannabis CBD lozenge to be introduced in Canada.
該產品由Vectura Fertin Pharma開發，代表了該公司在加拿大推出的首款醫療大麻CBD潤喉片。
The move follows the announced commercial collaboration between Vectura Fertin Pharma's subsidiary Cogent International and the Edmonton, Alberta-based company to leverage Aurora's Canadian medical cannabis patient platform.
此舉是繼Vectura Fertin Pharma子公司Cogent International與總部位於阿爾伯塔省埃德蒙頓市的公司宣佈商業合作之後，利用Aurora的加拿大醫療大麻患者平台。
Cogent manufactures, packages and labels the CBG lozenge, a novel dissolvable format and is easy to dose.
Cogent生產、包裝和標籤化的CBG潤喉片是一種新型可溶性格式，容易計量。
Read Also: Aurora Cannabis Shares Jump On Q1 FY25 Earnings, Global Medical Marijuana Yields Record Revenue Of $343M
閱讀也可以：極光大麻股份在2025財年第一季度宣佈，全球醫療大麻創造了343百萬美元的盈利創紀錄營收。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 獲取Benzinga獨家分析和大麻行業及市場的頭條新聞，每天免費發送到您的收件箱。請在這裏訂閱我們的新聞通訊。如果您對業務真誠地感興趣，就不能錯過這些。
Why It Matters
這爲以下原因非常重要
Through Aurora's patient platform, Cogent will gain access to patient feedback on the CBD lozenge, which will be used to validate the product proposition and build real-world patient data to inform future products.
通過極光的患者平台，Cogent將獲得關於CBD潛艾片的患者反饋，這將用於驗證產品主張並構建實際患者數據，以指導未來產品。
"As the leading provider of medical cannabis in Canada, the launch of the newly developed Luo CBD lozenge on our platform is a significant and exciting milestone at the beginning of our strategic collaboration with Vectura Fertin Pharma," said Aurora CEO Miguel Martin. "We are committed to bringing innovative solutions to patients and this launch reinforces our position at the forefront of Canada's medical cannabis industry."
「作爲加拿大醫療大麻的領先供應商，我們在Vectura Fertin Pharma平台上新開發的Luo CBD潛艾片的推出，標誌着我們與Vectura Fertin Pharma戰略合作的重大而令人興奮的里程碑，」 極光大麻CEO Miguel Martin表示。「我們致力於爲患者帶來創新解決方案，而這一推出進一步強化了我們在加拿大醫療大麻行業的領先地位。」
What's Next
接下來怎麼做
The two companies are open to exploring opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.
兩家公司願意探討有關在加拿大其他Vectura Fertin Pharma醫療大麻產品的潛在商業化機會。
ACB Price Action
ACB的價格行情
Aurora's shares traded 2.96% higher at $5.57 per share during the pre-market session on Monday morning.
週一早盤交易中，極光的股票以每股5.57美元的價格上漲了2.96%。
- NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership
- 納斯達克大麻股巨頭極光大麻通過這項新的CBD含片合作，可提升31%的銷售增長。
